IOLONCA Trademark

Trademark Overview

On Tuesday, January 23, 2018, a trademark application was filed for IOLONCA with the United States Patent and Trademark Office. The USPTO has given the IOLONCA trademark a serial number of 87765958. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 8, 2021. This trademark is owned by BeiGene, Ltd.. The IOLONCA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases
iolonca

General Information

Serial Number87765958
Word MarkIOLONCA
Filing DateTuesday, January 23, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 8, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 8, 2018

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 2, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBeiGene, Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1108
KY
Party NameBeiGene, Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1108
KY

Trademark Events

Event DateEvent Description
Monday, February 8, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 8, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 23, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 19, 2020EXTENSION 4 GRANTED
Friday, June 19, 2020EXTENSION 4 FILED
Friday, June 19, 2020TEAS EXTENSION RECEIVED
Monday, May 18, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 18, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 16, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 16, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, April 16, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 16, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, December 28, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 26, 2019EXTENSION 3 GRANTED
Thursday, December 26, 2019EXTENSION 3 FILED
Thursday, December 26, 2019TEAS EXTENSION RECEIVED
Friday, June 21, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 19, 2019EXTENSION 2 GRANTED
Wednesday, June 19, 2019EXTENSION 2 FILED
Wednesday, June 19, 2019TEAS EXTENSION RECEIVED
Wednesday, February 6, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 6, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 21, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 25, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 21, 2018EXTENSION 1 GRANTED
Friday, December 21, 2018EXTENSION 1 FILED
Friday, December 21, 2018TEAS EXTENSION RECEIVED
Tuesday, July 3, 2018NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 8, 2018PUBLISHED FOR OPPOSITION
Wednesday, April 18, 2018NOTICE OF PUBLICATION
Monday, April 2, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 26, 2018ASSIGNED TO EXAMINER
Friday, February 2, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, January 26, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

iolonca diseases infectious inflammatory autoimmune treatment cancer pharmaceuticals